2760 related articles for article (PubMed ID: 28489279)
1. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
2. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
3. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Madsen KS; Chi Y; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008558. PubMed ID: 31794067
[TBL] [Abstract][Full Text] [Related]
4. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
[TBL] [Abstract][Full Text] [Related]
5. Metformin monotherapy for adults with type 2 diabetes mellitus.
Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
9. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Hemmingsen B; Gimenez-Perez G; Mauricio D; Roqué I Figuls M; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003054. PubMed ID: 29205264
[TBL] [Abstract][Full Text] [Related]
10. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
11. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
[TBL] [Abstract][Full Text] [Related]
12. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
13. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
Lee SWH; Chen WS; Sellappans R; Md Sharif SB; Metzendorf MI; Lai NM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013178. PubMed ID: 37435938
[TBL] [Abstract][Full Text] [Related]
14. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
15. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Krogh J; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360
[TBL] [Abstract][Full Text] [Related]
17. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
19. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Davidson JA; Parente EB; Gross JL
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
[TBL] [Abstract][Full Text] [Related]
20. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]